Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Short term Debt (2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Short term Debt for 4 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $4.6 million for FY2025, N/A changed from the prior year.
  • Short term Debt for Q4 2025 was $4.6 million at Lexicon Pharmaceuticals, down from $42.1 million in the prior quarter.
  • The five-year high for Short term Debt was $42.1 million in Q1 2025, with the low at $4.6 million in Q4 2025.